Daniel Carlson

2385 POSTS 854 COMMENTS
Anixa

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Daniel Carlson -
0
Front Page

The Rare 10 Bagger Initiation

Daniel Carlson -
4
Front Page

Trading Update for Premium Subscribers 10-3-24

Daniel Carlson -
2
Anixa

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Daniel Carlson -
0
Front Page

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early...

Daniel Carlson -
0
Front Page

Darkest Before The Dawn? It’s Pitch Black Right Now

Daniel Carlson -
3
enVVeno

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Daniel Carlson -
3
Front Page

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary...

Daniel Carlson -
0
Front Page

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing...

Daniel Carlson -
0
Front Page

Aeluma Provides Fourth Quarter and Fiscal Year 2024 Results

Daniel Carlson -
0
Anixa

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Daniel Carlson -
0
Front Page

FED Cuts Rates…Micro-Caps Should Benefit (Eventually)

Daniel Carlson -
3
Uncategorized

Aeluma Wins $11.717 Million DARPA Contract for Nano-Scale Semiconductors

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at...

Daniel Carlson -
0
Front Page

Trading Update for Premium Subscribers

Daniel Carlson -
0
Front Page

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase...

Daniel Carlson -
0
Front Page

Aeluma Achieves ISO 9001:2015 Certification for Quality Management System

Daniel Carlson -
0
Front Page

There’s a Bull Market Somewhere

Daniel Carlson -
0
Front Page

INmune Bio Announces $13.0 Million Registered Direct Offering

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a...

Daniel Carlson -
3
Front Page

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine...

Daniel Carlson -
0
Front Page

Take Two Aspirin and Call Me In The Morning

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at...

Daniel Carlson -
0
enVVeno

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice...

Daniel Carlson -
1
Front Page

September Morn

Daniel Carlson -
6
Front Page

Go Time! It’s All About Execution

Daniel Carlson -
2
Front Page

What Does It All Mean?

Daniel Carlson -
4
enVVeno

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for...

Daniel Carlson -
0
Front Page

No Respect

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF...

Daniel Carlson -
0
Front Page

Taking Chips Off The Table…

Daniel Carlson -
1
Front Page

Anixa Update for Premium Subscribers

Daniel Carlson -
0
Front Page

PERMA-FIX ENVIRONMENTAL SERVICES ACQUIRES ENVIRONMENTAL WASTE OPERATIONS CENTER (EWOC) NEAR OAK...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial...

Daniel Carlson -
0
Front Page

Russell 2000 Powerhouse? The Underdog Climbs Again!

Daniel Carlson -
0
Front Page

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces FDA Approval of Individual Patient IND for its...

Daniel Carlson -
4
Atomera

Shawn Thomas Joins Atomera as VP of Marketing and Business Development

Daniel Carlson -
0
Front Page

Gold Continues to Shine

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces $5 Million Share Repurchase Program

Daniel Carlson -
0
Front Page

Close the Gap!

Daniel Carlson -
3
Front Page

A Tale of Two Tech Companies

Daniel Carlson -
1
Atomera

Atomera Enables Breakthrough RF Substrates for 5G Advanced and 6G Products

Daniel Carlson -
0
Front Page

Not Totally Blind…INmune Provides A Clue

Daniel Carlson -
4
Front Page

Premium Subscriber Update…June 27, 2024

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC)...

Daniel Carlson -
0
Anixa

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical...

Daniel Carlson -
0
Front Page

The Roller Coaster Ride Continues Unabated

Daniel Carlson -
3
Front Page

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100%...

Daniel Carlson -
0
Front Page

PERMA-FIX ENVIRONMENTAL SERVICES PROVIDES FURTHER UPDATES ON PATENT-PENDING PROCESS FOR DESTRUCTION...

Daniel Carlson -
2
Front Page

Mind the Gap…Micro Performance Continues to Suffer

Daniel Carlson -
0
Front Page

TFF Pharma…An Interview With The CEO

Daniel Carlson -
5
Front Page

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200...

Daniel Carlson -
0
Front Page

Cautious on The Market

Daniel Carlson -
14
Front Page

Aeluma Wins Another Funding Award from the Office of Secretary of...

Daniel Carlson -
0
Front Page

June Gloom

Daniel Carlson -
3
Front Page

IN8bio to Present at International Society for Cell & Gene Therapy...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the...

Daniel Carlson -
0
Front Page

Perma-Fix Announces Pricing of Approximately $20 Million Registered Direct Offering

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine...

Daniel Carlson -
0
Anixa

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T...

Daniel Carlson -
0
Front Page

It’s Getting Hot

Daniel Carlson -
4
Front Page

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase...

Daniel Carlson -
0
Front Page

Sell in May and Go Away

Daniel Carlson -
5
Front Page

PERMA-FIX REPORTS FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE FOR THE FIRST...

Daniel Carlson -
0
Front Page

QUEST RESOURCE HOLDING CORPORATION REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Daniel Carlson -
0
Front Page

Premium Subscriber Update, May 8, 2024

Daniel Carlson -
0
Anixa

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer...

Daniel Carlson -
0
Front Page

More Chatter on Financings…and Other Weekend Musings

Daniel Carlson -
14
Front Page

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

Daniel Carlson -
0
Front Page

INmune Bio Inc. Provides Update on Two Patients from the Phase...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of...

Daniel Carlson -
0
Front Page

Financing…Quality Matters

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market...

Daniel Carlson -
0
Front Page

Quest Resource Holding Corporation Announces Continued Strong Business Momentum and First...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase...

Daniel Carlson -
0
Front Page

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for...

Daniel Carlson -
0
Front Page

Premium Subscriber Update, April 22nd, 2024

Daniel Carlson -
0
Front Page

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through...

Daniel Carlson -
0
Front Page

Rocky Road to Success

Daniel Carlson -
0
Front Page

Quest Resource Announces Agreement With United Natural Foods, Inc To Help...

Daniel Carlson -
0
Anixa

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer...

Daniel Carlson -
0
enVVeno

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder...

Daniel Carlson -
2
Front Page

Golden Years?

Daniel Carlson -
2
IN8bio

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform...

Daniel Carlson -
0
enVVeno

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

Daniel Carlson -
0
Front Page

INmune Bio Inc. Presents Data on INB03’s Role as an Immune...

Daniel Carlson -
0
Front Page

Ciao from Sicily! Or, beheaded in Palermo…

Daniel Carlson -
2
Front Page

Movano Health Closes $24 Million Private Placement

Daniel Carlson -
0
Front Page

Premium Subscriber Easter Sunday Update…

Daniel Carlson -
3
Front Page

TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase...

Daniel Carlson -
4
Front Page

The Bull Market Trudges On…When Will It End?

Daniel Carlson -
4
Front Page

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under...

Daniel Carlson -
3
Front Page

TFFP Premium Subscriber Trading Update…

Daniel Carlson -
4
Front Page

TFF Pharmaceuticals Announces Update on Clinical Programs

Daniel Carlson -
0
Front Page

QUEST RESOURCE HOLDING CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 2023...

Daniel Carlson -
0
Front Page

Running in Place…It’s All About Execution

Daniel Carlson -
6
Front Page

Brief Update for Premium Subscribers…

Daniel Carlson -
0
Front Page

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT...

Daniel Carlson -
4
Anixa

Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress

Daniel Carlson -
0
Front Page

Spring Is Here…Micro-caps Are Emerging From Their Slumber

Daniel Carlson -
10
enVVeno

enVVeno Announces VenoValve Top Line Results…

Daniel Carlson -
4
enVVeno

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s...

Daniel Carlson -
0
Front Page

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform...

Daniel Carlson -
8
Front Page

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with...

Daniel Carlson -
0
Front Page

March Comes In Hot

Daniel Carlson -
6
enVVeno

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and...

Daniel Carlson -
0
Front Page

Trading Blog, Feb. 28, 2024

Daniel Carlson -
4
Front Page

Graduation Date

Daniel Carlson -
6
Atomera

Atomera to Present Joint Paper with Soitec and San Jose State...

Daniel Carlson -
0
Front Page

Trading Blog, Feb. 21, 2024

Daniel Carlson -
0
enVVeno

Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to...

Daniel Carlson -
0
Front Page

Biotech’s Next Move

Daniel Carlson -
17
Front Page

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple...

Daniel Carlson -
0
Front Page

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma...

Daniel Carlson -
0
Front Page

Aeluma Wins Funding Award from the Department of Energy

Daniel Carlson -
0
Anixa

Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T...

Daniel Carlson -
0
Front Page

Groupthink…It’s Not Always Wrong

Daniel Carlson -
4
Front Page

Trading Blog, Feb. 9, 2024

Daniel Carlson -
0
Front Page

Aeluma Wins Funding Award from the Office of the Secretary of...

Daniel Carlson -
0
Front Page

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on...

Daniel Carlson -
0
Front Page

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

Daniel Carlson -
0
Front Page

Good News Strikes Again…But This Time It’s Different

Daniel Carlson -
7
Front Page

Spectra7 and Teledyne LeCroy to Demonstrate Robust Performance Testing of 800Gbps...

Daniel Carlson -
1
Front Page

January 30th Trading Update

Daniel Carlson -
0
Front Page

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease...

Daniel Carlson -
0
Front Page

February Looms Large For Several TW Stocks

Daniel Carlson -
4
Front Page

Spectra7 and Keysight Successfully Achieve Robust Performance Testing of 800Gbps Active...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Daniel Carlson -
0
Front Page

Movano Health Announces Evie Rings Now Shipping

Daniel Carlson -
0
Front Page

Ice Fishing

Daniel Carlson -
1
Front Page

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS &...

Daniel Carlson -
0
Front Page

Spectra7 and Leading Equipment Suppliers to Demonstrate Robust Performance of 800Gbps...

Daniel Carlson -
0
Front Page

Spectra7 Receives Initial Order for Production GC1122 Chips

Daniel Carlson -
0
Front Page

Looking Asymmetrical

Daniel Carlson -
1
Front Page

Atomera Updates Revenue Guidance for the Fourth Quarter of 2023

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the...

Daniel Carlson -
0
Front Page

Time for the Russell to Close the Gap

Daniel Carlson -
4
Front Page

January Investment & Trading Thoughts

Daniel Carlson -
0
Front Page

Aeluma to Exhibit and Present at SPIE Photonics West January 30...

Daniel Carlson -
0
Front Page

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study...

Daniel Carlson -
0
Front Page

2023 Recap, 2024 Preview and Changes to the TW Universe

Daniel Carlson -
0
Front Page

Spectra7 Updates Expected Sales Outlook for the Year Ending December 31,...

Daniel Carlson -
4
Front Page

Happy Christmas

Daniel Carlson -
5
Front Page

Aeluma Appoints Seasoned Semiconductor Industry Executive Craig Ensley to its Board...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials...

Daniel Carlson -
2
Front Page

A Small Trade…and Thoughts on INMB

Daniel Carlson -
0
Front Page

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial...

Daniel Carlson -
0
Front Page

Ride The Bull

Daniel Carlson -
7
Front Page

TFF Pharmaceuticals Announces Reverse Stock Split

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

Daniel Carlson -
1
Front Page

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in...

Daniel Carlson -
0
Front Page

Mid December Trading Update

Daniel Carlson -
0
Front Page

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in...

Daniel Carlson -
1
Front Page

And The Answer Is…

Daniel Carlson -
3
Anixa

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase...

Daniel Carlson -
0
Front Page

My Rally Cap is On!

Daniel Carlson -
12
Front Page

Trading Thoughts…Premium Subscriber Update

Daniel Carlson -
5
Front Page

Movano Health Announces Over $1M Black Friday Holiday Launch Results for...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab...

Daniel Carlson -
0
Front Page

INmune Bio Receives EMA’s Authorization in France and Spain for Phase...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Daniel Carlson -
0
Front Page

The Outlook For December

Daniel Carlson -
9
Front Page

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed...

Daniel Carlson -
6
Front Page

Turkey Day is Coming…Micro-Caps Have Been Turkeys For A While

Daniel Carlson -
4
Front Page

Movano Health Announces Closing of $4.1 Million Public Offering Including Full...

Daniel Carlson -
0
enVVeno

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE)...

Daniel Carlson -
0
Front Page

The Year End Game Plan (part 2)…Premium Subscriber Update

Daniel Carlson -
3
Front Page

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for...

Daniel Carlson -
2
Atomera

Atomera Achieves Revenue Milestone Under First Commercial License Agreement

Daniel Carlson -
0
Front Page

It’s Not A Sprint (It’s a Marathon)

Daniel Carlson -
7
Front Page

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery...

Daniel Carlson -
0
Front Page

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to...

Daniel Carlson -
0
Front Page

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial...

Daniel Carlson -
0
Front Page

Rates Cease Their Upward March (for now…)

Daniel Carlson -
2
Front Page

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC)...

Daniel Carlson -
0
Front Page

IN8bio to Present New Positive Data from Phase 1 Trial of...

Daniel Carlson -
0
Anixa

Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA)...

Daniel Carlson -
0
Front Page

Movano Health’s Proprietary Chip and Prototype Achieves Accuracy Commensurate with the...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03...

Daniel Carlson -
0
Front Page

In Support of the XBI

Daniel Carlson -
3
Front Page

Spectra7 Announces Preliminary Third Quarter 2023 Revenue and Updates Second Half...

Daniel Carlson -
3
Front Page

The Year End Game Plan…Premium Subscriber Update

Daniel Carlson -
4
Anixa

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark...

Daniel Carlson -
0
Front Page

Testing Support…(Not Likely to Hold in TW’s Opinion)

Daniel Carlson -
0
Front Page

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase...

Daniel Carlson -
0
Front Page

Supply and Demand

Daniel Carlson -
6
Anixa

Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer...

Daniel Carlson -
2
Front Page

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a...

Daniel Carlson -
0
Front Page

Choose Wisely

Daniel Carlson -
4
enVVeno

NVNO in the News Today…Premium Subscriber Update

Daniel Carlson -
0
enVVeno

enVVeno Medical Announces New Expedited Development Plan for the enVVe® Transcatheter...

Daniel Carlson -
0
enVVeno

enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Daniel Carlson -
0
enVVeno

enVVeno Medical Announces Private Placement of $28 Million

Daniel Carlson -
4
Anixa

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer...

Daniel Carlson -
0
Front Page

Time for the Little Guys to Shine…4th Quarter Preview

Daniel Carlson -
1
Front Page

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC)...

Daniel Carlson -
0
Front Page

IN8bio to Host Research & Development Day on its Gamma-Delta T...

Daniel Carlson -
0
Front Page

TW Trade Alert, Sept. 27, 2023

Daniel Carlson -
0
Front Page

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study...

Daniel Carlson -
0
Front Page

Jumping Beans

Daniel Carlson -
5
Front Page

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Daniel Carlson -
0
Anixa

Anixa Biosciences Establishes Cancer Business Advisory Board

Daniel Carlson -
0
Front Page

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation...

Daniel Carlson -
0
Front Page

Meaningful Catalysts

Daniel Carlson -
8
Front Page

Spectra7 Announces Convertible Debenture Unit Financing

Daniel Carlson -
0
Front Page

Is the Ice Thawing? XBI Acting Slightly Better…

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces Approval of Clinical Trial Application by the...

Daniel Carlson -
0
Front Page

Wrapping up Summer

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T...

Daniel Carlson -
0
Front Page

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the...

Daniel Carlson -
0
Front Page

Know What You Own…

Daniel Carlson -
2
Front Page

Spectra7 Announces Second Quarter 2023 Financial Results

Daniel Carlson -
0
Front Page

Fitch Kills The Rally

Daniel Carlson -
1
Front Page

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate...

Daniel Carlson -
2
Front Page

Premium Subscriber Update: TFF Raises Money at $0.25…What Does It Mean?

Daniel Carlson -
6
Anixa

Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at...

Daniel Carlson -
0
Front Page

INmune Updates Shareholders and Other Thoughts

Daniel Carlson -
6
Front Page

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research...

Daniel Carlson -
0
Front Page

Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing...

Daniel Carlson -
0
Anixa

Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One...

Daniel Carlson -
0
Front Page

August 7, 2023…Premium Subscriber Update

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing...

Daniel Carlson -
0
Front Page

Asking For Compassion From TFF

Daniel Carlson -
9
Front Page

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening...

Daniel Carlson -
0
Front Page

XBI…Waiting For The Breakout

Daniel Carlson -
5
Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian...

Daniel Carlson -
3
Front Page

In Search of the Holy Grail

Daniel Carlson -
4
Front Page

July 19, 2023…Premium Subscriber Update

Daniel Carlson -
0
Front Page

Spectra7 Announces Preliminary Second Quarter 2023 Revenue and Second Half of...

Daniel Carlson -
0
Front Page

Things are Heating Up

Daniel Carlson -
6
enVVeno

enVVeno Medical to Host Virtual KOL Event on July 18, 2023

Daniel Carlson -
0
Front Page

July 14, 2023…Premium Subscriber Update

Daniel Carlson -
0
Front Page

July 12, 2023…Premium Subscriber Update

Daniel Carlson -
3
Front Page

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in...

Daniel Carlson -
0
Front Page

INmune Bio Inc. Announces Data Presented at the 16th European Meeting...

Daniel Carlson -
0
Front Page

QUEST RESOURCE HOLDING CORPORATION APPOINTS INDUSTRY VETERAN, PERRY W. MOSS, AS...

Daniel Carlson -
0
Front Page

It’s Beach Week And The Sun Was Shining On TW’s Names

Daniel Carlson -
5
enVVeno

enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study...

Daniel Carlson -
0
Front Page

Where to Find Fireworks? We Go Looking.

Daniel Carlson -
5
Front Page

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

Daniel Carlson -
2
Front Page

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing...

Daniel Carlson -
0
Front Page

Free Call Options

Daniel Carlson -
6
Front Page

June 20, 2023…Premium Subscriber Update

Daniel Carlson -
13
Front Page

Several Updates

Daniel Carlson -
8
Front Page

Movano Health Prices $8.0 Million Public Offering

Daniel Carlson -
0
Front Page

June 13, 2023…Premium Subscriber Update

Daniel Carlson -
0
Front Page

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate...

Daniel Carlson -
0
Front Page

The Spotlight Turns to INmune Bio…

Daniel Carlson -
10
Front Page

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug...

Daniel Carlson -
0
Front Page

June 8, 2023…Premium Subscriber Update

Daniel Carlson -
0
Front Page

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at...

Daniel Carlson -
0
Front Page

Wrapping Up May

Daniel Carlson -
8
Front Page

Keep The Faith…Rubber Eventually Meets Road

Daniel Carlson -
9
Front Page

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present...

Daniel Carlson -
0
Front Page

May 22, 2023…Premium Subscriber Update

Daniel Carlson -
3
Anixa

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer...

Daniel Carlson -
3
Front Page

Back in the Saddle

Daniel Carlson -
3
Front Page

IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

Daniel Carlson -
0
Front Page

Spectra7 Announces 50% Y-o-Y Revenue Growth in First Quarter 2023, Affirms...

Daniel Carlson -
0
Newsletters

Upcoming Catalysts For A Catalyst Driven Market

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental...

Daniel Carlson -
5
Front Page

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented...

Daniel Carlson -
0
Front Page

May 2, 2023…Trading Update

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized...

Daniel Carlson -
0
Front Page

This Time It’s Different!

Daniel Carlson -
10
Front Page

April 27th, 2023 Trade Update…ATOM and INAB

Daniel Carlson -
1
Atomera

Atomera Signs Commercial License Agreement with STMicroelectronics

Daniel Carlson -
1
Front Page

April 26, 2023 Trade Update

Daniel Carlson -
5
Front Page

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in...

Daniel Carlson -
0
Front Page

Spectra7 Announces 107% Revenue Growth for 2022, Pre-announces Q1 2023 and...

Daniel Carlson -
0
Front Page

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and...

Daniel Carlson -
0
Front Page

Anixa Delivers On The Data While The Stock Rollercoasters

Daniel Carlson -
3
Front Page

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

Daniel Carlson -
0
Anixa

Recapping Anixa…Premium Subscriber Update

Daniel Carlson -
5
Anixa

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1...

Daniel Carlson -
0
Anixa

Anixa’s Breast Cancer Vaccine Looks Spot On…An Interview With Dr. Amit...

Daniel Carlson -
1
Front Page

IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches...

Daniel Carlson -
0
Front Page

Coming Out Of Hibernation?

Daniel Carlson -
7
Front Page

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent...

Daniel Carlson -
0
Front Page

IN8bio to Present New Positive Clinical Data from Phase 1 Trial...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR...

Daniel Carlson -
0
Front Page

How Low Can It Go?

Daniel Carlson -
1
Front Page

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application...

Daniel Carlson -
0
Front Page

Three Months Down

Daniel Carlson -
5
Front Page

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study,...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
0
Front Page

3 Dot Lounge…

Daniel Carlson -
5
Front Page

Movano Health Provides Business Update and Reports Fourth Quarter 2022 Financial...

Daniel Carlson -
0
Front Page

Upcoming Catalysts (or, Meaningful Events That Probably Won’t Help Your Portfolio)

Daniel Carlson -
2
Front Page

March 17, 2023 Trade Update

Daniel Carlson -
0
Front Page

IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform...

Daniel Carlson -
0
Front Page

Movano Health Awarded Three New Core Patents Validating its Cutting-Edge Approach...

Daniel Carlson -
0
Front Page

Premium Subscriber Update SPVNF, March 14th

Daniel Carlson -
4
Front Page

Spectra7 Announces 112G PAM4 Design-In with Zhaolong for North American and...

Daniel Carlson -
0
Front Page

Black Swan Diving

Daniel Carlson -
12
Front Page

Spectra7 Microsystems Inc. Announces Private Placement of $5.89 Million CAD

Daniel Carlson -
0
Front Page

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the...

Daniel Carlson -
0
Front Page

What Women Want: Accuracy is Critical to Future Wearable Use

Daniel Carlson -
4
Front Page

INmune Bio: Things Turning For The Better

Daniel Carlson -
7
Front Page

Premium Subscriber Update INMB, TFFP, SPVNF & BWLKF

Daniel Carlson -
6
Front Page

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing...

Daniel Carlson -
0
Front Page

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on...

Daniel Carlson -
0
Front Page

Market Tests Support…Here’s What To Do.

Daniel Carlson -
4
Front Page

Trade Alert for Premium Subscribers, Feb. 23 2023

Daniel Carlson -
4
Front Page

IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board

Daniel Carlson -
0
Front Page

Trading Update for Premium Subscribers, Feb. 18, 2023

Daniel Carlson -
4
Front Page

Execution is Key

Daniel Carlson -
15
Front Page

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform,...

Daniel Carlson -
0
Front Page

Spectra7 Announces New 800Gbps Design Win with ACES for North American...

Daniel Carlson -
0
Front Page

Ruminating On INmune, Anixa and More

Daniel Carlson -
18
Front Page

Spectra7 Targets High Growth 800Gbps AI Server Market

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development...

Daniel Carlson -
0
Front Page

Trading Update, February 8th 2023

Daniel Carlson -
1
Front Page

Double Trouble

Daniel Carlson -
9
Front Page

Spectra7 to Showcase 200 and 400Gbps Connectivity using Active Copper Cables...

Daniel Carlson -
0
Uncategorized

Awaiting Liftoff…Catalyst List

Daniel Carlson -
6
Front Page

Trading Update, January 27th 2023

Daniel Carlson -
0
Front Page

Movano Health Prices $6.5 Million Public Offering

Daniel Carlson -
0
Front Page

INmune in DMD…Yet Another Indication of Future Success

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach...

Daniel Carlson -
0
Front Page

Looking for 3-5X This Year? These Two Jackpot Stocks Offer That...

Daniel Carlson -
2
Front Page

Spectra7 Announces Preliminary Fourth Quarter and Annual Financial Results for the...

Daniel Carlson -
0
enVVeno

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and...

Daniel Carlson -
0
Front Page

Notes for Premium Subscribers

Daniel Carlson -
9
Front Page

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path...

Daniel Carlson -
0
Front Page

The January Halftime Report

Daniel Carlson -
4
Front Page

The 2023 Game Plan

Daniel Carlson -
1
Front Page

Spectra7, ACON, and Mo-Link to Demonstrate Thunderbolt 4 Active Copper Cables...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief...

Daniel Carlson -
6
Front Page

For The TW Portfolio, Our FATE Awaits

Daniel Carlson -
6
Uncategorized

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284...

Daniel Carlson -
0
Front Page

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

Daniel Carlson -
2
Front Page

IN8bio to Present at Biotech Showcase 2023 in San Francisco

Daniel Carlson -
0
Front Page

The Light at the End of the Tunnel

Daniel Carlson -
9
Front Page

Trading Thoughts As We Prepare To Swap Out The Calendar

Daniel Carlson -
0
Front Page

Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely...

Daniel Carlson -
2
Front Page

Trading Alert: Initiating a New Position

Daniel Carlson -
3
Front Page

Holiday Cheers!

Daniel Carlson -
0
Front Page

Movano Health On Track to File First FDA Submission for its...

Daniel Carlson -
0
Front Page

Movano Health Announces Launch of Smart Ring Beta Program with Novant...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284...

Daniel Carlson -
0
Front Page

Santa Claus Ain’t Coming To Town

Daniel Carlson -
11
Anixa

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell...

Daniel Carlson -
2
Front Page

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Leadership Transition

Daniel Carlson -
5
Front Page

Informed Decisions

Daniel Carlson -
8
Front Page

Spectra7 Announces Third Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance...

Daniel Carlson -
0
Front Page

Pardon Me

Daniel Carlson -
2
Front Page

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug...

Daniel Carlson -
0
Front Page

Pot Watching…

Daniel Carlson -
14
Front Page

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

Daniel Carlson -
10
Front Page

Trading Blog, November 17, 2022

Daniel Carlson -
5
Front Page

Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium...

Daniel Carlson -
0
Front Page

Trading Blog, November 16, 2022

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence...

Daniel Carlson -
0
Front Page

Crashing Bitcoins and Other Thoughts

Daniel Carlson -
18
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
0
Front Page

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve...

Daniel Carlson -
0
Front Page

Dinner Table Talk

Daniel Carlson -
12
Front Page

ParkerVision Secures Patent License Agreement with Hisense

Daniel Carlson -
3
Front Page

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop...

Daniel Carlson -
6
Front Page

TFF Delays Data and Other Thoughts Heading Into Year-End 2022

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus...

Daniel Carlson -
12
Front Page

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder...

Daniel Carlson -
5
Front Page

Sanford M. Litvack Joins ParkerVision Board of Directors

Daniel Carlson -
0
Anixa

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer...

Daniel Carlson -
0
Front Page

Counting Down to Catalysts

Daniel Carlson -
13
Front Page

Spectra7 Announces Return of Chief Executive Officer Raouf Halim to Half...

Daniel Carlson -
1
Front Page

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast...

Daniel Carlson -
0
Front Page

Keeping An Eye On The Trees

Daniel Carlson -
5
Front Page

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple...

Daniel Carlson -
0
Front Page

Resetting Expectations

Daniel Carlson -
7
Front Page

Spectra7 Announces Preliminary Third Quarter 2022 Revenue and Second Half 2022...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film...

Daniel Carlson -
4
Anixa

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at...

Daniel Carlson -
0
Front Page

Bringing Down the House

Daniel Carlson -
21
Front Page

Welcome Back???

Daniel Carlson -
7
Front Page

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous...

Daniel Carlson -
0
Front Page

Trading Alert, Sept. 15th, 2022

Daniel Carlson -
0
Front Page

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of...

Daniel Carlson -
0
Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the...

Daniel Carlson -
0
Front Page

Moving Day

Daniel Carlson -
15
Front Page

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder...

Daniel Carlson -
1
Front Page

Don’t Fight The FED. TW’s August Recap.

Daniel Carlson -
0
Front Page

The Bear Returns

Daniel Carlson -
9
Uncategorized

Spectra7 Announces Closing of the Upsized Convertible Debenture Financing of $8.9...

Daniel Carlson -
0
Front Page

Spectra7 Announces Upsizing of Convertible Debenture Financing to $9.0 Million

Daniel Carlson -
0
Front Page

When News Is Good

Daniel Carlson -
0
Front Page

Trading Alert, August 18th, 2022

Daniel Carlson -
0
Front Page

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

Daniel Carlson -
0
Anixa

CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer...

Daniel Carlson -
0
Front Page

Pendulum Swings

Daniel Carlson -
5
Front Page

Movano Expands Go-To-Market Team with Vice President of UX and UI...

Daniel Carlson -
0
Front Page

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring...

Daniel Carlson -
0
Front Page

The Domino Effect

Daniel Carlson -
11
Front Page

Trading Alert, August 5th, 2022

Daniel Carlson -
0
Front Page

Trading Alert, August 2nd, 2022

Daniel Carlson -
0
Front Page

Micros Rallied in July, Can It Continue?

Daniel Carlson -
3
Front Page

Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche

Daniel Carlson -
0
Fortress Bio

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral...

Daniel Carlson -
0
Uncategorized

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in...

Daniel Carlson -
0
Front Page

Dog Days of Summer

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast...

Daniel Carlson -
2
Front Page

Trading Alert, July 19th, 2022

Daniel Carlson -
2
Front Page

Taking the Long View on TFF

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

Daniel Carlson -
3
Front Page

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical...

Daniel Carlson -
0
Front Page

Catalysts Aplenty, a 2nd Half Preview

Daniel Carlson -
1
Front Page

Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint

Daniel Carlson -
2
Front Page

enVVeno Medical Announces the Issuance of a New Unique Category III...

Daniel Carlson -
0
Amryt

Amryt Presents New Analyses from the EASE Phase 3 Trial in...

Daniel Carlson -
0
Front Page

June in Review

Daniel Carlson -
3
Front Page

This Week’s Newsletter

Daniel Carlson -
0
Amryt

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional...

Daniel Carlson -
0
Front Page

Spectra7 Expands Availability of Active Copper Cables with new Design-in with...

Daniel Carlson -
0
Front Page

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS...

Daniel Carlson -
2
Anixa

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and...

Daniel Carlson -
0
Anixa

Going Downhill

Daniel Carlson -
2
Front Page

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on...

Daniel Carlson -
0
Amryt

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED...

Daniel Carlson -
0
Anixa

High Degree of Confidence

Daniel Carlson -
7
Amryt

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials...

Daniel Carlson -
0
Atomera

June Gloom

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial...

Daniel Carlson -
0
Front Page

Spectra7 Announces First Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

Establishing Lows

Daniel Carlson -
2
Front Page

INMB: Making Sense of The FDA Clinical Hold

Daniel Carlson -
5
Front Page

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as...

Daniel Carlson -
1
Anixa

CEO Knows Best

Daniel Carlson -
2
Fortress Bio

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency...

Daniel Carlson -
0
Front Page

Quest Resource Holding Corporation Reports First Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

INmune Bio Looks to Change The CNS Landscape

Daniel Carlson -
1
Front Page

It’s Still The Early Innings

Daniel Carlson -
11
Front Page

Movano Successfully Completes Functional Testing of Smallest Ever Custom mmWave Sensor...

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business...

Daniel Carlson -
4
Front Page

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray...

Daniel Carlson -
1
Anixa

Stepping on Rakes

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business...

Daniel Carlson -
0
Front Page

Top Global Virtual Reality Gaming Company Chooses Spectra7 Chipset to Power...

Daniel Carlson -
0
Front Page

enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin...

Daniel Carlson -
0
Front Page

Spectra7 Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Daniel Carlson -
0
Anixa

The Rolling Correction Gathers Steam…

Daniel Carlson -
3
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
2